Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|July 18, 2020
- Ophthalmology Times: July 1, 2020
- Volume 45
- Issue 11
A sight for sore eyes
Author(s)Jon Carter
Advertisement
Articles in this issue
about 6 years ago
Pearls for managing COVID-19 pandemic north of the borderover 6 years ago
Stepping up to meet visual needs of refugees in Bangladeshover 6 years ago
Investigators target algorithm for diagnosing glaucomaover 6 years ago
Ultra-widefield imaging can enhance efficiency for practicesover 6 years ago
Study targets results of MIGS device versus trabeculectomyover 6 years ago
Getting it right: There is no magic bullet for IOL calculationsover 6 years ago
Surgeons discuss MIPS, impact of pass-through medicationsover 6 years ago
For IOL placement, location is keyAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5